Full Press Release Details
Rhythm Pharmaceuticals Announces New Data Presentations on Patients with Acquired or Congenital Hypothalamic Obesity N 35 Treated with Setmelanotide for up to Nine Months in French.
RYTM
Rhythm Pharmaceuticals Announces New Data Presentations on Patients with Acquired or Congenital Hypothalamic Obesity N 35 Treated with Setmelanotide for up to Nine Months in French
Key Takeaway: Rhythm Pharmaceuticals Announces New Data Presentations on Patients with Acquired or Congenital Hypothalamic Obesity N 35 Treated with Setmelanotide for up to Nine Months in French